treatment-resistant depression
Articles tagged with “treatment-resistant depression”
Treatment-Resistant Depression: Why Antidepressants Fail
A Hindu report on treatment-resistant depression explains why antidepressants fail for some patients and where ketamine and esketamine fit in.
Ketamine Eases Suicidal Thoughts, But Does It Save Lives?
A 2026 review in Psychiatric Times finds ketamine and ECT rapidly ease suicidal thoughts, but proof they prevent attempts or deaths is limited.
Bipolar Depression Ketamine Trial: One Patient's Experience
A clinical trial patient says ketamine changed his life for bipolar depression. Here's what the report does and doesn't tell readers, and how to weigh it.
BPL-003 Reaches Phase III in Treatment-Resistant Depression
AtaiBeckley advances BPL-003 into Phase III for treatment-resistant depression. What this milestone means for patients and the TRD treatment landscape.
New Study: Ketamine Relieves Treatment-Resistant Depression
A new study reports ketamine relieves treatment-resistant depression and suicidal ideation. What the research means for patients exploring their options.
Ketamine for Depression: Why Your GP Stays Silent
Ketamine is producing real results for treatment-resistant depression, yet most GPs don't raise it. Here's what patients need to know about access and options.
Boston Clinics Spotlight Ketamine's Growing Role in Mental Health
Boston clinics are expanding ketamine therapy for mental health. What patients should know about access, cost, and what to expect from treatment.
Is Ketamine the Future of Mental Health Treatment?
A local news segment spotlights ketamine therapy's growing role in mental health. Here's what the coverage gets right, and what patients should know.
Psych Deprescribing Debate: What It Means for Ketamine
HHS targets psychiatric overprescribing. Experts say stop what's not working, and replace it with evidence-based alternatives. Here's how ketamine fits in.
Faster TRD Remission: Why Measurement-Based Care Matters
New clinical guidance on TRD emphasizes fast dose adjustments and symptom tracking, here's what it means for patients considering ketamine therapy.
Faster TRD Remission: What Smarter Dosing Means for You
New guidance on treatment-resistant depression stresses faster dose adjustments and symptom tracking. Here's what it means for ketamine therapy patients.
Ketamine Side Effects: What the Data Now Shows
New clinical guidance on NMDA antagonist side effects and discontinuation rates gives ketamine patients a clearer picture of what to expect and when to switch.
Ketamine vs. Esketamine: Side Effects and Who Stops Treatment
New clinical guidance on NMDA antagonist side effects and dropout rates helps patients make smarter choices about ketamine-based depression treatment.
Ketamine for TRD Works Better When Clinics Measure It
New research highlights how symptom tracking and dose optimization help treatment-resistant depression patients reach remission faster with ketamine.
Faster TRD Remission: What Better Protocols Mean for You
New guidance on TRD treatment highlights faster dose adjustment and symptom tracking. Here's what it means for patients considering ketamine.
Getting TRD Patients to Remission Faster in 2026
New analysis in Psychiatric Times shows measurement-based care and rapid dose adjustment get TRD patients to remission faster, here's what that means for ketamine.
How Active Clinical Management Speeds Up TRD Recovery
New analysis shows faster symptom tracking and dose adjustments lead to quicker TRD remission, here's what that means for ketamine therapy.
BPL-003 Shows Lasting Relief for Treatment-Resistant Depression
New phase 2a results for BPL-003 show sustained symptom reduction in treatment-resistant depression. What this means for ketamine patients.
Esketamine's Role in Treatment-Resistant Depression
Esketamine (Spravato) for treatment-resistant depression: how it works, who qualifies, REMS clinic visits, cost ranges, and Spravato vs IV ketamine.
Why Settling for 'Less Bad' Depression Isn't Enough
Clinicians are pushing for aggressive TRD care aimed at full remission. Here's what that means for patients exploring ketamine treatment options.
BPL-003 Shows Lasting TRD Relief in Phase 2a Results
New phase 2a data on BPL-003 shows sustained symptom reduction in treatment-resistant depression. Here's what it means for ketamine patients.
New Ketamine Nasal Spray Shows Lasting Depression Relief
BPL-003, a novel ketamine nasal spray for treatment-resistant depression, shows sustained symptom reduction in Phase 2a trials. What patients should know.
Contact Ketamine Resource
Send corrections, partnership questions, or advertising inquiries.